Iovance Biotherapeutics Inc (NASDAQ:IOVA)
| 25.35 BATS BZX Real-Time Price As of 12:38pm ET |  +0.41 / +1.64%Today’s Change | 15.88 Today|||52-Week Range 54.21 | -45.37% Year-to-Date |
Latest IOVA News | Press Releases
| HOOKIPA (HOOK), Merck Collaborate to Treat Head & Neck Cancers Sep 16 / Zacks.com - Paid Partner Content | Why Iovance Is Up Nearly 11% Today Sep 15 / MotleyFool.com - Paid Partner Content |
Today’s Trading
| Previous close | 24.94 |
| Today’s open | 25.00 |
| Day’s range | 24.81 - 25.99 |
| Volume | 46,214 |
| Average volume (3 months) | 2,912,667 |
| Market cap | $3.9B |
Data as of 12:38pm ET, 09/27/2021
Growth & Valuation
| Earnings growth (last year) | -18.13% |
| Earnings growth (this year) | -11.78% |
| Earnings growth (next 5 years) | -19.00% |
| Revenue growth (last year) | -- |
| P/E ratio | NM |
| Price/Sales | -- |
| Price/Book | 5.60 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| EDITEditas Medicine Inc | -0.24 | -0.41% |
| IBRXImmunitybio Inc | +0.35 | +3.42% |
| ALLOAllogene Therapeutic... | +0.05 | +0.19% |
| NKTRNektar Therapeutics | +0.43 | +2.32% |
Data as of 12:38pm ET, 09/27/2021
Financials
| Next reporting date | November 10, 2021 |
| EPS forecast (this quarter) | -$0.53 |
| Annual revenue (last year) | $0.00 |
| Annual profit (last year) | -$259.6M |
| Net profit margin | -- |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters San Carlos, California |
Forecasts
